Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever

Virology Journal

Volumn 7, Issue , 2010, Pages

  Branco, Luis M ^a,b   Grove, Jessica N ^a   Geske, Frederick J ^c   Boisen, Matt L ^c   Muncy, Ivana J ^c   Magliato, Susan A ^d   Henderson, Lee A ^e   Schoepp, Randal J ^f   Cashman, Kathleen A ^f   Hensley, Lisa E ^f   Garry, Robert F ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Autoimmune Technologies LLC   (United States)

^c Division of Medicine   (United States)

^d TULANE UNIVERSITY   (United States)

^e Vybion Inc   (United States)

^f UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 2; GLYCOPROTEIN GP1; LECTIN; NUCLEOPROTEIN; SMALL SUBUNIT RIBOSOMAL RNA; UNCLASSIFIED DRUG; Z MATRIX PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT VACCINE; VIROSOME VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COMPARTMENTALIZATION; CELL STRAIN HEK293; CELL STRUCTURE; CYTOTOXICITY; DEGLYCOSYLATION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMORRHAGIC FEVER; LASSA HEMORRHAGIC FEVER; LASSA VIRUS; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN GLYCOSYLATION; RIBOSOME; RNA ANALYSIS; VIRION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LASSA FEVER; METHODOLOGY; VACCINATION;

ANIMALIA; LASSA VIRUS; MAMMALIA; MUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LASSA FEVER; LASSA VIRUS; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIRAL PROTEINS; VIRAL VACCINES;

EID: 77957993361     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-279     Document Type: Article

References (66)

1. Lassa fever vaccine: A review. SP Fisher-Hoch JB McCormick, Expert Rev Vaccines 2004 3 103 111 10.1586/14760584.3.2.189 (Pubitemid 38470528)
2. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. JB McCormick, Med Microbiol Immunol 1986 175 153 155 10.1007/BF02122438 3724661
3. Epidemiology and control of Lassa fever. JB McCormick, Current Topics in Microbiol and Immunol 1987 134 69 78
4. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. SP Fisher-Hoch O Tomori A Nasidi GI Perez-Oronoz Y Fakile L Hutwagner JB McCormick, Br Med J 1995 311 857 859
5. A prospective study of the epidemiology and ecology of Lassa fever. JB McCormick PA Webb JW Krebs KM Johnson ESES Smith, J Infect Dis 1987 155 437 444 3805771
6. Lassa fever. Effective therapy with ribavirin. JB McCormick IJ King PA Webb CL Scribner RB Craven KM Johnson LH Elliot R Belmont-Williams, N Engl J Med 1986 314 20 26 10.1056/NEJM198601023140104 3940312
7. Arenaviridae: The viruses and their replication. MJ Buchmeier MD Bowen CJ Peters, Fields Virology Philadelphia: Lippincott-Raven, Knipe DM, Howley PM, 4 2001 1635 1668
8. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. O Lenz J ter Meulen HD Klenk NG Seidah W Garten, Proc Natl Acad Sci USA 2001 A98 12701 12705 10.1073/pnas.221447598 (Pubitemid 33020009)
9. The viral transmembrane superfamily: Possible divergence of arenavirus and filovirus glycoproteins from a common RNA virus ancestor. WR Gallaher C DiSimone MJ Buchmeier, BMC Microbiol 2001 1 1 10.1186/1471-2180-1-1 11208257
10. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. DG Bausch PE Rollin AH Demby M Coulibaly J Kanu AS Conteh KD Wagoner LK McMullan MD Bowen CJ Peters T Ksiazek, J Clin Microbiol 2000 38 2670 2677 10878062
11. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. MM Illick LM Branco JN Fair KA Illick A Matschiner R Schoepp RF Garry MC Guttieri, Virology J 2008 5 161 10.1186/1743-422X-5-161
12. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. LM Branco RF Garry, Virology J 2009 6 147 10.1186/1743-422X-6-147
13. Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. SL Ruo SW Mitchell MP Killey LF Roumillat SP Fisher-Hoch JB McCormick, J Gen Virol 1991 72 549 555 10.1099/0022-1317-72-3-549 1706408
14. Structural and cell-associated proteins of Lassa virus. JCS Clegg G Lloyd, J Gen Virol 1983 64 1127 1136 10.1099/0022-1317-64-5-1127 6405010
15. Localization of an arenavirus protein in the nuclei of infected cells. PR Young AC Chanas SR Lee EA Gould CR Howard, J Gen Virol 1987 68 2465 2470 10.1099/0022-1317-68-9-2465 3309183
16. Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies. FT Hufert W Ludke H Schmitz, Arch Virol 1989 106 201 212 10.1007/BF01313953 2476109
17. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa glycoprotein gene. SP Fisher-Hoch JB McCormick D Auperin BG Brown M Castor,, et al. Proc Natl Acad Sci USA 1989 86 317 321 10.1073/pnas.86.1.317 2911575
18. Effective vaccine for Lassa fever. SP Fisher-Hoch L Hutwagner B Brown JB McCormick, J Virol 2000 74 6777 6783 10.1128/JVI.74.15.6777-6783.2000 10888616
19. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. P Pushko J Geisbert M Parker P Jahrling J Smith, J Virol 2001 75 23 11677 11685 10.1128/JVI.75.23. 11677-11685.2001 11689649
20. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. PJ Bredenbeek R Molenkamp WJ Spaan V Deubel P Marianneau MS Salvato D Moshkoff J Zapata I Tikhonov J Patterson R Carrion A Ticer K Brasky IS Lukashevich, Virol 2006 345 2 299 304 10.1016/j.virol.2005.12.001 (Pubitemid 43189891)
21. Development of a new vaccine for the prevention of Lassa fever. TW Geisbert S Jones EA Fritz AC Shurtleff JB Geisbert R Liebscher A Grolla U Ströher L Fernando KM Daddario MC Guttieri BR Mothé T Larsen LE Hensley PB Jahrling H Feldmann, PLoS Med 2005 2 6 183 Epub 2005 Jun 28 10.1371/journal.pmed.0020183 15971954
22. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever. JC Clegg G Lloyd, Lancet 1987 2 8552 186 188 10.1016/S0140-6736(87)90767-7 2885642
23. Viral protein determinants of Lassa virus entry and release from polarized epithelial cells. K Schlie A Maisa F Freiberg A Groseth T Strecker W Garten, J Virol 2010 84 7 3178 3188 10.1128/JVI.02240-09 20071570
24. Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). R Eichler T Strecker L Kolesnikova J ter Meulen W Weissenhorn S Becker HD Klenk W Garten O Lenz, Virus Res 2004 100 2 249 255 10.1016/j.virusres.2003.11. 017 15019244
25. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. T Strecker A Maisa S Daffis R Eichler O Lenz W Garten, Virol J 2006 3 93 10.1186/1743-422X-3-93 17083745
26. Baculovirus expression of the glycoprotein gene of Lassa virus and characterization of the recombinant protein. KB Hummel ML Martin DD Auperin, Virus Res 1992 25 1-2 79 90 10.1016/0168-1702(92)90101-E 1413995
27. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. O Lenz J ter Meulen HD Klenk NG Seidah W Garten, Proc Natl Acad Sci USA 2001 98 22 12701 12705 10.1073/pnas.221447598 11606739
28. Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach. M Moerdyk-Schauwecker SI Hwang VZ Grdzelishvili, Virol J 2009 6 166 10.1186/1743-422X-6-166 19821998
29. ExPASy PeptideCutter tool: Protein Identification and Analysis Tools on the ExPASy Server. E Gasteiger C Hoogland A Gattiker S Duvaud MR Wilkins RD Appel A Bairoch, The Proteomics Protocols Handbook, Humana Press, John M Walker, 2005
30. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. LM Branco A Matschiner JN Fair A Goba DB Sampey PJ Ferro KA Cashman RJ Schoepp RB Tesh DG Bausch RF Garry MC Guttieri, Virol J 2008 5 74 10.1186/1743-422X-5-74 18538016
31. Cellular factors required for Lassa virus budding. S Urata T Noda Y Kawaoka H Yokosawa J Yasuda, J Virol 2006 8 4191 4195 10.1128/JVI.80.8.4191- 4195.2006
32. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. EM Broomall SM Reynolds RM Jacobson, Postgrad Med 2010 122 2 121 129 10.3810/pgm.2010.03.2129 20203463
33. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. SL Block DR Brown A Chatterjee MA Gold HL Sings A Meibohm A Dana RM Haupt E Barr GM Tamms H Zhou KS Reisinger, Pediatr Infect Dis J 2010 29 2 95 101 10.1097/INF.0b013e3181b77906 19952863
34. Efficacy of human papillomavirus vaccines: a systematic quantitative review. LR Medeiros DD Rosa MI da Rosa MC Bozzetti RR Zanini, Int J Gynecol Cancer 2009 19 7 1166 1176 19823051
35. Post licensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. BA Slade L Leidel C Vellozzi EJ Woo W Hua A Sutherland HS Izurieta R Ball N Miller MM Braun LE Markowitz J Iskander, JAMA 2009 302 7 750 757 19 10.1001/jama.2009.1201 19690307
36. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. MH Einstein M Baron MJ Levin A Chatterjee RP Edwards F Zepp I Carletti FJ Dessy AF Trofa A Schuind G Dubin, Hum Vaccin 2009 5 10 705 719 10.4161/hv.5.10.9518 19684472
37. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. N Mũoz R Manalastas Jr P Pitisuttithum D Tresukosol J Monsonego K Ault C Clavel J Luna E Myers S Hood O Bautista J Bryan FJ Taddeo MT Esser S Vuocolo RM Haupt E Barr A Saah, Lancet 2009 373 9679 1949 1957 10.1016/S0140-6736(09)60691-7 19493565
38. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. JA Suzich SJ Ghim FJ Palmer-Hill WI White JK Tamura JA Bell JA Newsome AB Jenson R Schlegel, Proc Natl Acad Sci USA 1995 92 25 11553 11557 10.1073/pnas.92.25.11553 8524802
39. GlaxoSmithKline plc, http://us.gsk.com/products/assets/us-engerixb.pdf
40. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. P Pushko T Kort M Nathan MB Pearce G Smith TM Tumpey, Vaccine 2010 28 30 4771 4776 10.1016/j.vaccine.2010.04.093 20470801
41. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. K Mahmood RA Bright N Mytle DM Carter CJ Crevar JE Achenbach PM Heaton TM Tumpey TM Ross, Vaccine 2008 26 42 5393 5399 10.1016/j.vaccine.2008.07.084 18706956
42. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. RA Bright DM Carter CJ Crevar FR Toapanta JD Steckbeck KS Cole NM Kumar P Pushko G Smith TM Tumpey TM Ross, PLoS One 2008 3 1 1501 10.1371/journal.pone.0001501 18231588
43. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. P Pushko TM Tumpey N Van Hoeven JA Belser R Robinson M Nathan G Smith DC Wright RA Bright, Vaccine 2007 25 21 4283 4290 10.1016/j.vaccine.2007.02.059 17403562
44. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. RA Bright DM Carter S Daniluk FR Toapanta A Ahmad V Gavrilov M Massare P Pushko N Mytle T Rowe G Smith TM Ross, Vaccine 2007 25 19 3871 3878 10.1016/j.vaccine.2007.01.106 17337102
45. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. DL Swenson KL Warfield DL Negley A Schmaljohn MJ Aman S Bavari, Vaccine 2005 23 23 3033 3042 10.1016/j.vaccine. 2004.11.070 15811650
46. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. KL Warfield DL Swenson GG Olinger WV Kalina MJ Aman S Bavari, J Infect Dis 2007 196 Suppl 2 430 437 10.1086/520583 17940980
47. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. DL Swenson KL Warfield T Larsen DA Alves SS Coberley S Bavari, Expert Rev Vaccines 2008 7 4 417 429 10.1586/14760584.7.4.417 18444889
48. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. G Spohn GT Jennings BE Martina I Keller M Beck P Pumpens AD Osterhaus MF Bachmann, Virol J 2010 7 1 146 10.1186/1743-422X-7-146 20604940
49. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. DE Purdy GJ Chang, Virol 2005 333 2 239 250 10.1016/j.virol.2004.12.036 (Pubitemid 40250108)
50. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. MR Murawski LW McGinnes RW Finberg EA Kurt-Jones MJ Massare G Smith PM Heaton AE Fraire TG Morrison, J Virol 2010 84 2 1110 1123 10.1128/JVI.01709-09 19889768
51. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIC-1 virus-like particle in vivo: implications on HIV vaccine development. R Wagner L Deml R Schirmbeck J Reimann H Wolf, Behring Inst Mitt 1994 95 23 34 7755506
52. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. CY Kang L Luo MA Wainberg Y Li, Biol Chem 1999 380 3 353 364 10.1515/BC.1999.047 10223338
53. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. X Paliard Y Liu R Wagner H Wolf J Baenziger CM Walker, AIDS Res Hum Retroviruses 2000 16 3 273 282 10.1089/088922200309368 10710215
54. The basis for HIV immunotherapeutic vaccines. BS Peters, Vaccine 2001 20 5-6 688 705 10.1016/S0264-410X(01)00394-2 11738732
55. Virus-like particles as HIV-1 vaccines. LX Doan M Li C Chen Q Yao, Rev Med Virol 2005 15 2 75 88 10.1002/rmv.449 15484204
56. Virus-like particles: designing an effective AIDS vaccine. KR Young SP McBurney LU Karkhanis TM Ross, Methods 2006 40 1 98 117 10.1016/j.ymeth.2006.05. 024 16997718
57. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). M Mihailova M Boos I Petrovskis V Ose D Skrastina M Fiedler I Sominskaya S Ross P Pumpens M Roggendorf S Viazov, Vaccine 2006 24 20 4369 4377 10.1016/j.vaccine.2006.02.051 16574285
58. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. PT Vietheer I Boo HE Drummer HJ Netter, Antivir Ther 2007 12 4 477 487 17668556
59. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. I Sominskaya D Skrastina A Dislers D Vasiljev M Mihailova V Ose D Dreilina P Pumpens, Clin Vaccine Immunol 2010 17 6 1027 1033 10.1128/CVI.00468-09 20410327
60. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. W Akahata ZY Yang H Andersen S Sun HA Holdaway WP Kong MG Lewis S Higgs MG Rossmann S Rao GJ Nabel, Nat Med 2010 16 3 334 338 10.1038/nm.2105 20111039
61. Novavax, Inc, http://www.novavax.com/download/releases/4-29-10- PhaseIIa202study-rs.pdf
62. Novavax, Inc, http://www.novavax.com/download/releases/SeroFO.pdf
63. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. G Köhler C Milstein, Eur J Immunol 1976 6 7 511 519 10.1002/eji.1830060713 825377
64. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. G Köhler SC Howe C Milstein, Eur J Immunol 1976 6 4 292 5 10.1002/eji.1830060411 825374
65. Continuous cultures of fused cells secreting antibody of predefined specificity. G Köhler C Milstein, Nature 1975 256 5517 495 497 10.1038/256495a0 1172191
66. Molecular Cloning. A Laboratory Manual. J Sambrook EF Fritsch T Maniatis, Cold Spring Harbor Laboratory Press Second 1989